Ezetimibe: uses, dosing, side effects & brands

Zetia (Ezetimibe) is a dietary cholesterol absorption inhibitor used to treat Hypercholesterolemia, Hyperlipoproteinemia Type II, Familial Combined Hyperlipidemia.

The FDA classifies ezetimibe as a dietary cholesterol absorption inhibitor. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The elimination half-life of ezetimibe is about 22 hours — that is how long the body takes to clear half of a dose. Linear, non-saturable elimination. Ezetimibe is rapidly conjugated to its active metabolite ezetimibe-glucuronide (which makes up ~80-90% of circulating drug and is also pharmacologically active); the metabolite shares the same ~22-hour half-life, so it does not meaningfully outlast the parent. Ezetimibe is NOT a prodrug — the parent compound is itself active. Extensive enterohepatic recycling produces multiple plasma concentration peaks and sustains exposure, so it takes roughly 4-5 days (about 5 half-lives) to clear the system. Plasma levels are higher in older adults and rise substantially with hepatic impairment (not recommended in moderate-to-severe liver disease) and with severe renal impairment. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run ezetimibe against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

Across the brands we track, ezetimibe is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

We do not currently list a generic-labelled ezetimibe product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

The FDA's Enforcement database lists 1 recall record whose product description mentions ezetimibe. The most recent: Ezetimibe and Simvastatin Tablets (May 19, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

In monotherapy trials of the 10 mg tablet (the only strength sold; brand name Zetia), the side effects reported more often than with placebo were upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), joint pain (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), pain in an arm or leg (2.7% vs 2.5%), fatigue (2.4% vs 1.5%), and flu (2.0% vs 1.5%). Notice how close the placebo numbers are — ezetimibe alone is one of the better-tolerated cholesterol drugs, which is why it is often used when statins cause problems.

Two do-not-use situations. First, a known hypersensitivity to ezetimibe or any ingredient in the tablet. Second — and this is the one people miss — ezetimibe is contraindicated in anyone for whom the statin, fenofibrate, or other LDL-lowering drug it is being combined with is itself contraindicated. So if you cannot take the statin, you cannot take the combination; the ezetimibe does not make the statin safer. Ezetimibe is also not recommended in moderate to severe liver impairment (Child-Pugh class B or C), because blood levels rise and the effects are unknown.

Yes, though it is uncommon. The label states ezetimibe may cause myopathy — muscle pain, tenderness, or weakness with an elevated creatine kinase level — and rhabdomyolysis. In post-marketing reports, most people who developed rhabdomyolysis were also taking a statin or another drug known to raise that risk, such as a fibrate. If muscle symptoms appear, ezetimibe and the other suspect medicines should be stopped. Report unexplained muscle pain, tenderness, or weakness, particularly with fever or dark urine.

Ezetimibe can raise liver enzymes, and the risk is higher in combination. In controlled trials where ezetimibe and a statin were started together, consecutive ALT or AST elevations of 3 times the upper limit of normal occurred in 1.3% of patients versus 0.4% on a statin alone. The label says to do liver enzyme testing as clinically indicated and to consider stopping ezetimibe if those elevations persist. Ask your doctor whether you need baseline and follow-up liver panels, especially if you are on a statin too.

Three interactions matter. Cyclosporine raises ezetimibe levels and ezetimibe raises cyclosporine levels — if both are used, cyclosporine concentrations should be monitored. Fenofibrate plus ezetimibe can both push cholesterol into the bile and lead to gallstones, so gallbladder imaging is warranted if gallstone symptoms appear; combining ezetimibe with fibrates other than fenofibrate is not recommended. Bile acid sequestrants such as cholestyramine cut how much ezetimibe you absorb, so take ezetimibe at least 2 hours before or 4 hours after the sequestrant. Standard dosing is 10 mg once daily, with or without food. In pregnancy, ezetimibe should be used only if the potential benefit justifies the risk to the fetus — data in pregnant women are insufficient — and it should not be used while nursing unless the benefit justifies the risk to the infant.